Loading...
ALXP
ALINS
Market cap12mUSD
Oct 28, Last price  
0.20EUR
1D
2.00%
1Q
-9.73%
Jan 2017
-66.00%
IPO
-97.17%
Name

Intrasense SA

Chart & performance

D1W1MN
ALXP:ALINS chart
P/E
—
P/S
3.64
EPS
—
Vol. 1Y
97.39%
Shs. 5Y
—
Rev. 5Y
5.85%
Div Yld LY
—
Div Yld TTM
—
Revenues
3m
2,963,325
Net income
-11m
-10,809,000
CFO

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Established in 2004 and headquartered in Montpellier, France, Intrasense S.A. specializes in the global development of sophisticated software for visualizing and analyzing diverse medical imaging data, marketed under its Myrian brand. The company's offerings feature the Myrian Imaging Layer, a versatile multi-modality visualization platform tailored for professionals in the health industry. It also provides Myrian Studio, a dedicated development environment empowering innovators, industrial partners, spin-offs, and research institutions to build medical imaging applications. Furthermore, Intrasense leverages its Myrian technologies to facilitate the creation of biomarkers and artificial intelligence solutions. A key component of its product line is Myrian Clinical Apps, an extensive collection of advanced post-processing clinical applications. This portfolio encompasses specialized modules like Myrian XP-Breast, XP-Prostate, XP-Liver, XP-Mammo, XP-Lung, XP-Colon, XP-Vessel, and XP-Cardiac, alongside Myrian XL-Onco for tracking lesions. These applications, which also provide solutions for analyzing specific pathologies or organs, offer various tools for interpreting data from MRI, CT scans, conventional radiology, and nuclear imaging examinations.

Related entities

Parent

Key people

Deputy Chief Executive Officer · since 2017
Stephane Chemouny
Director · since 2018
Eric Le Bihan
Director
Olivier Marrot
Director
Patrick Mayette
Director · since 2014
IPO date
Feb 22, 2012
Employees
61
Domiciled in
FR
Incorporated in
FR
Headquarters & legal address
1231 AVENUE DU MONDIAL 98
MONTPELLIER 34000
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FY
2025‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT